Incidence of apoptosis, cell proliferation and p53 expression in renal cell carcinomas

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 1155-1162

  Tannapfel, Andrea ^a   Hahn, Helmut A ^a   Katalinic, Alexander ^b   Fietkau, Rainer J ^b   Kühn, Reinhard ^b   Wittekind, Christian W ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apoptosis; p53; Prognosis; Proliferation; Renal carcinoma

Indexed keywords

ANTIBODY; CYCLINE; KI 67 ANTIGEN; MUTANT PROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL DIVISION; HUMANS; KIDNEY NEOPLASMS; MUTATION; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030997972     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Vaux DL: Toward an understanding of the molecular mechanism of physiological cell death. Proc Natl Acad Sci USA 90: 786-789, 1993.
2. Smith ML, Chen IT, Zhan Q, O Connor PM, Fornace AJ Jr: Involvement of pS3 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10: 1053-1059, 1995.
3. Carson DA and Lois A: Cancer progression and p53. Lancet 346: 1009-1011, 1995.
4. deRiese W, Crabtree WN, Allhoff E, Werner M, Liedke S, Lenis G, Atzpodien J, Kirchner H: Prognostic significance of Ki-67 Immunostaining in nonmetatastatic renal cell carcinoma. J Clin ollcol 9: 1804-1808, 1993.
5. Ansari B, Coates PJ, Greenstein BD, Hall PA: In situ end labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 770: 1-8, 1993.
6. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, Lassmann H: Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 71: 219-225, 1994.
7. Mostofi KF, Sesterhenn IA, Sobin LH: Histological typing of kidney tumours. International histological classification of tumours. No 25. Genf: WHO 1981.
8. UJICC: TNM classification of malignant tumors. 4th ed. 2nd revision. Hermanek P, Sobin I,H, editors.; Berlin: Springer-Verlag. 1992.
9. Hermanek P, Schrott KM: Evaluation of the new tumor, nodes and metastases classification of renal cell carcilloma. J Urol 144: 238-242, 1990.
10. Uhlman DL, Nguyen PL, Manivel C, Aeppli D, Resnick JM, Fraley EE, Zhung G, Niehans GA: Association of immunostaining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86: 1470-1475, 1994.
11. Chemeris G, Loktinov A, Rempel A, Schwarz M, Bannasch P: Elevated cotent of p53 in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Arcll 176: 563-560, 1995.
12. Schwartz LM, Oshorne BA: Programmed cell death, apoptosis and killer cells. Immunol Today 14: 582-590, 1993.
13. Tinnemunns MM, Lenders MH, tcn-Velde GP, Ramaekers FC, Schutte B: Alterations in cytoskletal and nuclear matrix-associated proteins during apoptosis. Eur J Cell Biol 68: 35-46, 1995.
14. Leoncini L, DelVecchion MT, Megha T, Barhini P, Galieni P, Pileri S, Sabattini E, Gherlinzoni F, Tosi P, Kraft R, Cottier H: Correlations between apoptotic and proliferative indices in malignant Non Hodgkin s Lymphomas. Am J Pathol 142: 755-763, 1993.
15. Lipponen PK, Aallomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 17: 333-339, 1994.
16. Levine EL, Renehan A, Gossiel R. Duvidson SE, Roberts SA, Chadwick C, Wilks DP, Potten CS, Hendry JH, Hunter RD: Apoptosis. intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 37: 1-9, 1995.
17. Kong J, Ringer. DP: Quantitative in situ image analysis of apoptosis in well and poorly differentiated tumors from rat liver. Am J Pathol 147: 1626-1632, 1995.
18. Bot FJ, Godschalk CJ, Krishnadath KK, VanDerKwast THM, Bosman FT: Prognostic factors in renal cell carcinoma: Immunohistochemical detection of p53 protein versus clinicopathological parameters. Int J Cancer 57: 634-637, 1994.
19. Soddu S, Blandino G, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M, Sacchi A: Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol Cell Biol 16: 487-495, 1996.
20. Wang XW, Gibson MK, Vermeulen W. Yen H, Forrester K, Sturzbecher HW, Hoeijemakers JH, Harris CC: Abrogation of p53- induccd apoptosis by the hepatitis B virus X gene. Cancer Res 55: 6012-6016, 1995.
21. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78: 539-542, 1994.
22. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, VanDyke T: p53dcpendent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711, 1994.
23. Montie JE: Prognostic factors for renal cell carcinoma. J Urol 152: 1397-1398, 1994.